Fortrea, a renowned global contract research organization (CRO), has recently concluded the divestiture of its Enabling Services segment assets, encompassing Endpoint Clinical (Endpoint) and Fortrea Patient Access (FPA) businesses, to Arsenal Capital Partners. This strategic move establishes Fortrea’s commitment to building market-leading, technology-rich healthcare and industrial growth companies, in collaboration with Arsenal, a prominent private equity firm.
The deal, finalized on June 4th, 2024, signifies Fortrea’s ongoing efforts to focus on its core competencies and strengthen its position as a leading player in the CRO industry. By divesting the Endpoint Clinical and Fortrea Patient Access businesses, Fortrea is streamlining its operations and allocating resources towards its primary expertise in contract research.
Arsenal Capital Partners, renowned for its specialization in developing market-leading, technology-driven healthcare and industrial growth companies, proved to be an ideal partner for Fortrea. The collaboration ensures a seamless transition and offers promising opportunities for future growth and innovation in the healthcare sector.
Endpoint Clinical, a part of Fortrea’s Enabling Services segment, caters to the pharmaceutical, biotech, and medical device industries by providing technology-driven clinical research solutions. Fortrea Patient Access (FPA) is an essential component of Fortrea’s integrated patient recruitment offering, enabling efficient and cost-effective engagement with patients and sites.
The divestiture enables both Fortrea and Arsenal to optimize their respective strengths. Fortrea can now concentrate on its core CRO capabilities, offering comprehensive clinical research services to its clients. Meanwhile, Arsenal can leverage its expertise in building technology-rich and market-leading healthcare companies to enhance the performance of Endpoint Clinical and Fortrea Patient Access, propelling them to new heights of success.
This strategic move not only aligns with Fortrea’s long-term goals but also ensures that both Endpoint Clinical and Fortrea Patient Access continue their growth trajectory autonomously under Arsenal’s stewardship. Through this collaboration, Fortrea aims to foster innovation, drive operational excellence, and deliver superior value to its clients, while Arsenal capitalizes on its technological prowess to enhance the performance of the divested businesses.
With this successfully concluded divestiture, the stage is set for Fortrea’s continued growth and expansion. By partnering with Arsenal Capital Partners, a leader in private equity specializing in building technology-rich healthcare and industrial growth companies, Fortrea symbolizes its unwavering commitment to remaining at the forefront of the ever-evolving clinical research landscape.
As Fortrea embarks on the next phase of its growth journey, propelled by a renewed focus on its core CRO capabilities, the divestiture of Endpoint Clinical and Fortrea Patient Access businesses marks a significant milestone. Fortrea’s partnership with Arsenal paves the way for exciting new opportunities, reinforcing its resilience and ensuring that it remains a driving force in the global contract research organization arena.
Comments